No profile data available.
Verastem, Inc. (VSTM) is a healthcare company in the additional cancer treatment drugs industry, based in Needham, United States, with about 102 full-time employees.
It reported revenue of $10.00 million for fiscal year 2024, and net income of -$130.64 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $11.24 million. Its market capitalization was $758.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Verastem reported $10.00 million in revenue for fiscal year 2024. In Q3 2025 revenue was $11.24 million.
$758.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Replimune Group, Inc. (REPL), ArriVent BioPharma, Inc. (AVBP), Candel Therapeutics, Inc. (CADL), Nuvectis Pharma, Inc. (NVCT).